NORTH KINGSTOWN, R.I., Sept. 30, 2014 /PRNewswire/ -- Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and actionable clinical information, now offers a new laboratorybased urine test for the detection of commonly prescribed ZDrugs.

“ZDrugs” are a class of nonbenzodiazepine medications prescribed mainly for the treatment of insomnia. Included in this group are zolpidem (Ambien®), eszopiclone (Lunesta®) and zaleplon (Sonata®). Their growth in popularity has been due to their being promoted as an alternative drug class that exhibits clinical effects similar to benzodiazepines but with less potential to cause side effects such as residual daytime sedation and rebound insomnia.

Despite their claim to be safer than benzodiazepines, ZDrugs, particularly zolpidem, have become popular among recreational drug users, who describe visual effects, euphoric experiences and hallucinations. Tolerance, dependence and withdrawal are all reported with these drugs, although it tends to be less severe and less common than with benzodiazepines. Withdrawal symptoms include delirium, craving, anxiety, tremor, palpitations and rarely seizures and psychosis.

The potential for abuse exists for all Z-Drugs but appears to be most common with zolpidem and eszopiclone. Zolpidem has been noted as the drug most often implicated in emergency room visits, accounting for 11.5% of all adult psychiatric medication adverse drug effect visits. In visits involving adults 65 years or older, it was involved 21% of the time.

Dominion’s testing for ZDrugs is performed by ultra performance liquid chromatography/tandem mass spectrometry (UPLCMS/MS) and detects zolpidem, zolpidem metabolite, eszopiclone, eszopiclone metabolite and zaleplon.

“The addition of ZDrugs to our testing menu is important as we see increased popularity in Z-Drugs prescribed as sleep aids,” said Lawrence Andrade, Manager of Research and Development at Dominion Diagnostics. “Although they are mainly used for the same purpose, ZDrugs are chemically distinct from benzodiazepine medications and will not be detected in a benzodiazepines screening test or confirmatory procedure.”

References are on file at Dominion Diagnostics.

About Dominion Diagnostics
Dominion Diagnostics is a leading national laboratory that offers clinical drug testing, prescription monitoring services, and a full suite of clinical support solutions. Since 1997, Dominion Diagnostics has provided services to clients representing a diversity of medical specialties across the United States, including addiction medicine, behavioral health, pain medicine, primary care, psychiatry, and hospital systems. Dominion Diagnostics is supported by a worldclass team that shares a commitment to clinical excellence, compliance, and integrity. For more information, please visit www.dominiondiagnostics.com.

For Media Relations, contact:
Julie K. Lenahan, MBA, Director of Marketing, Dominion Diagnostics, (401) 6670876,
jlenahan@dominiondiagnostics.com

Logo - http://photos.prnewswire.com/prnh/20140204/NE57628LOGO

SOURCE Dominion Diagnostics